Senior executives in clinical development and operations from the world’s top pharmaceutical, biotech and medical device companies will be joined by experts in medical innovation to deliver keynote presentations on a range of emerging technological and patient-centric issues at the 24th Annual Partnerships in Clinical Trials (“PCT”) conference in Boston, MA, taking place April 22-24, 2015.
According to conference co-chair Jodie Morrison, President and CEO of Tokai Pharmaceuticals, this year’s PCT keynotes—several of whom have been recruited from outside the clinical research field—and the topics they will be covering reflect an urgent need in the clinical research industry to better understand how rapid technological innovation and the changing role of the patient are revolutionizing clinical development.
“The field of medicine is evolving rapidly and the complexities of both research and clinical development are increasing as a result,” said Morrison. “There is a critical need for a much broader set of tools and an increased focus on evaluating trends to ensure the success of clinical development in this new environment.”
“This year’s Partnerships in Clinical Trials keynotes will focus on new initiatives, broadening technology options and expanded opportunities that we simply can’t afford to ignore,” she added.
PCT 2015 keynotes will include visionaries from outside the clinical development field who will speak to how medical informatics, personalized medicine, patient trends and technology are transforming clinical research, including:
● “Can Big Data Cure Cancer?”
Atul Butte, MD, PhD, Director, Institute for Computational Health Sciences, and Professor of Pediatrics, University of California, San Francisco
A world-renowned medical informatics expert, Dr. Butte explains why the title of his keynote, “Can Big Data Cure Cancer?” is an increasingly rhetorical question thanks to extraordinary advancements in computational health and how Big Data analytics will impact clinical research.
● “Fast Tracking Clinical Development in a Moment's Notice: Patient Advocacy, Social Media and the Implications of Compassionate Use”
Kenneth Moch, former CEO, Chimerix
As CEO of a small biotech caught between the realities of getting a developmental drug approved and an aggressive social media campaign to get a seven-year-old cancer patient pre-approval access to it, Ken Moch explains how social media can derail clinical development almost overnight and what manufacturers—particularly resource-strapped biotechs—can do to prepare.
● “Connecting the Innovation Dots: Solutions to the Disconnection between the Pace of Technology and Traditional Approaches to Clinical Trials”
Donald Jones, Chief Technology Officer, Scripps Translational Science Institute
Advances in digital technology are enabling researchers to collect different kinds of outcomes data in new ways and promise to provide a more complete and accurate picture of patients and the effect of therapies in studies. Donald Jones shares the latest on connected solutions to increase patient engagement and how information tools are transforming clinical trials.
● “Picking up the Pieces of Clinical Trial Failure: How I Battled the FDA and Won”
Dr. Joseph Gulfo, former President and CEO, MELA Sciences and author of "Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances"
Small companies—typically startups—today comprise the backbone of the drug and medical device innovation pipeline. For these companies to successfully develop a breakthrough depends as much on their ability to contend with investors and regulators as it does on smart science. Dr. Gulfo imparts the survival skills necessary to innovate in a hostile environment.
Additional keynote panels featuring industry leaders, policy experts and actual patients will bring a truly unique and diverse perspective to topics crucial to the future of clinical development, including:
With an eye toward partnering to adapt in an increasingly complex environment, PCT 2015 will feature nearly 150 speakers in keynotes and across eight specialized breakout tracks with exciting new unfiltered, unscripted and unedited formats spanning think tanks, case insights, intensives, and other interactive sessions, alongside results-oriented, innovative networking opportunities and special events like the 4th Annual Women’s Clinical Leadership Forum.
Approximately 1100 attendees representing more than 125 biopharma and medical device companies, contract research organizations (CROs) and other suppliers from nearly 50 countries are expected to attend PCT 2015, which promises to deliver data and insights that have never been heard before and real-world solutions to pressing new challenges in the world’s largest networking forum for clinical decision makers and their partners.
For more information or to register today, please visit www.clinicaltrialpartnerships.com
ABOUT PARTNERSHIPS IN CLINICAL TRIALS
With 23 years serving professionals in clinical development and operations, trials and outsourcing, Partnerships in Clinical Trials is the world’s foremost event series for clinical development leaders and practitioners. Annually, more than 2000 executives representing biopharma sponsors, CROs and third-party services providers attend Partnerships in Clinical Trial meetings in the US, Latin America, Europe and Asia to network, learn, strategize and advance next practices. Partnerships in Clinical Trials is produced by the Institute for International Research (IIR) and committed to redefining clinical research excellence on a global scale.